Compare GKOS & PPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | PPC |
|---|---|---|
| Founded | 1998 | 1946 |
| Country | United States | United States |
| Employees | N/A | 52100 |
| Industry | Medical/Dental Instruments | Meat/Poultry/Fish |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.7B |
| IPO Year | 2015 | 1997 |
| Metric | GKOS | PPC |
|---|---|---|
| Price | $126.04 | $30.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 3 |
| Target Price | ★ $126.92 | $41.33 |
| AVG Volume (30 Days) | 1.3M | ★ 1.3M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 6.74% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | $507,442,000.00 | ★ $18,497,553,000.00 |
| Revenue This Year | $23.32 | $2.46 |
| Revenue Next Year | $27.43 | $1.83 |
| P/E Ratio | ★ N/A | $69.40 |
| Revenue Growth | ★ 32.33 | 3.46 |
| 52 Week Low | $73.16 | $27.13 |
| 52 Week High | $148.11 | $50.56 |
| Indicator | GKOS | PPC |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 52.77 |
| Support Level | $94.16 | $27.25 |
| Resistance Level | $147.43 | $38.86 |
| Average True Range (ATR) | 7.18 | 0.95 |
| MACD | 1.01 | 0.39 |
| Stochastic Oscillator | 91.26 | 90.95 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed JBS's offer undervalued Pilgrim's Pride.